Prot #0103-020: A Phase 1/2 Study of HDAC Inhibitor, Mocetinostat, in Combination With PD-L1 Inhibitor, Durvalumab, in Advanced or Metastatic Solid Tumors and Non-Small Cell Lung Cancer

Project: Research project

Project Details

StatusFinished
Effective start/end date12/16/16 → 12/16/22

Funding

  • PRA Health Sciences (Prot #0103-020)
  • Mirati Therapeutics Inc. (Prot #0103-020)